Though lung cancer looks promising a partner is now needed.
ApexOnco Front Page
Recent articles
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
The company ditches lorigerlimab in prostate cancer.
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
New detalimogene bladder cancer data send the minnow’s stock up 47%.
The response rate jumps to 30% with higher doses of IMA402.
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
After more discontinuations, a new deal brings in fresh blood.
